New views on pathogenesis and diagnosis of peritoneal carcinomatosis

Peritoneal metastasis occurs in a number of heterogeneous tumors originating from the ovaries, stomach, intestines, pancreas, lungs, breast, and melanoma. Peritoneal carcinomatosis significantly reduces overall survival. While being almost unresponsive to treatment, dissemination of tumor cells along the peritoneum aggravates the course of the disease. Despite the use of locoregional treatment, peritoneal carcinomatosis is still considered to be an aggravating factor with a poor prognosis. Peritoneal carcinomatosis cannot be defined as a separate locoregional process with its own biology and oncogenesis due to the lack of clear understanding the molecular and biological features of peritoneal metastasis, as well as generally recognized standards for diagnosis and treatment of malignant neoplasms with various localizations. Addressing peritoneal carcinomatosis as a separate developing molecular event will enhance the understanding of its morpho- and oncogenesis and strengthen the search for therapeutic, diagnostic and preventive approaches to its management. Th e paper presents a bibliographic study of publications on exploring peritoneal metastases from various sites, including the abdominal and pelvic organs. Th e known mechanisms of tumors metastasis to the peritoneum are characterized in the paper. Diagnostic approaches to peritoneal carcinomatosis were assessed and compared. Th e collected data analysis revealed the main gaps in the understanding of peritoneal carcinomatosis oncogenesis.

1. Li J., Guo T. Role of peritoneal mesothelial cells in the progression of peritoneal metastases. Cancers (Basel). 2022;14(12):2856. DOI: 10.3390/cancers14122856

2. Peng S., Chen D., Cai J., Yuan Z., Huang B., Li Y., et al. Enhancing cancer-associated fibroblast fatty acid catabolism within a metabolically challenging tumor microenvironment drives colon cancer peritoneal metastasis. Mol Oncol. 2021;15(5):1391–411. DOI: 10.1002/1878-0261.12917

3. Sánchez-Hidalgo J.M., Rodríguez-Ortiz L., Arjona-Sánchez Á., Rufián-Peña S., Casado-Adam Á., Cosano-Álvarez A., et al. Colorectal peritoneal metastases: Optimal management review. World J Gastroenterol. 2019;25(27):3484–502. DOI: 10.3748/wjg.v25.i27.3484

4. Leiting J.L., Grotz T.E. Optimizing outcomes for patients with gastric cancer peritoneal carcinomatosis. World J Gastrointest Oncol. 2018;10(10):282–9. DOI: 10.4251/wjgo.v10.i10.282

5. Franko J. Therapeutic efficacy of systemic therapy for colorectal peritoneal carcinomatosis: Surgeon’s perspective. Pleura Peritoneum. 2018;3(1):20180102. DOI: 10.1515/pp-2018-0102

6. Quénet F., Elias D., Roca L., Goéré D., Ghouti L., Pocard M., et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256–66. DOI: 10.1016/S1470-2045(20)30599-4

7. McMullen J.R.W., Selleck M., Wall N.R., Senthil M. Peritoneal carcinomatosis: limits of diagnosis and the case for liquid biopsy. Oncotarget. 2017;8(26):43481–90. DOI: 10.18632/oncotarget.16480

8. Kim S.H., Choi Y.H., Kim J.W., Oh S., Lee S., Kim B.G., et al. Clinical significance of computed tomography-detected ascites in gastric cancer patients with peritoneal metastases. Medicine (Baltimore). 2018;97(8):e9343. DOI: 10.1097/MD.0000000000009343

9. Ritch S.J., Telleria C.M. The Transcoelomic ecosystem and epithelial ovarian cancer dissemination. Front Endocrinol (Lausanne). 2022;13:886533. DOI: 10.3389/fendo.2022.886533

10. Mutsaers S.E., Prêle C.M., Pengelly S., Herrick S.E. Mesothelial cells and peritoneal homeostasis. Fertil Steril. 2016;106(5):1018–24. DOI: 10.1016/j.fertnstert.2016.09.005

11. Hu Q., Xia X., Kang X., Song P., Liu Z., Wang M., et al. A review of physiological and cellular mechanisms underlying fibrotic postoperative adhesion. Int J Biol Sci. 2021;17(1):298–306. DOI: 10.7150/ijbs.54403

12. Capobianco A., Cottone L., Monno A., Manfredi A.A., RovereQuerini P. The peritoneum: healing, immunity, and diseases. J Pathol. 2017;243(2):137–47. DOI: 10.1002/path.4942

13. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;1:571–3. DOI: 10.1016/S0140-6736(00)49915-0

14. Ewing J. Neoplastic Diseases: a treatise on tumours. Br. J. Surg. 1928;16:174–5. DOI: 10.1002/bjs.1800166126

15. Sugarbaker E.V. Cancer metastasis: a product of tumor-host interactions. Curr Probl Cancer. 1979;3:1–59. DOI: 10.1016/S0147-0272(79)80008-2

16. Deguchi A., Maru Y. Inflammation-associated premetastatic niche formation. Inflamm Regen. 2022;42(1):22. DOI: 10.1186/s41232-022-00208-8

17. Klymenko Y., Kim O., Loughran E., Yang J., Lombard R., Alber M., et al. Cadherin composition and multicellular aggregate invasion in organotypic models of epithelial ovarian cancer intraperitoneal metastasis. Oncogene. 2017;36(42):5840–51. DOI: 10.1038/onc.2017.171

18. Mikuła-Pietrasik J., Uruski P., Tykarski A., Książek K. The peritoneal “soil” for a cancerous “seed”: a comprehensive review of the pathogenesis of intraperitoneal cancer metastases. Cell Mol Life Sci. 2018;75(3):509–25. DOI: 10.1007/s00018-017-2663-1

19. Deng G., Qu J., Zhang Y., Che X., Cheng Y., Fan Y., et al. Gastric cancer-derived exosomes promote peritoneal metastasis by destroying the mesothelial barrier. FEBS Lett. 2017;591(14):2167–79. DOI: 10.1002/1873-3468.12722

20. Dhaliwal D., Shepherd T.G. Molecular and cellular mechanisms controlling integrin-mediated cell adhesion and tumor progression in ovarian cancer metastasis: a review. Clin Exp Metastasis. 2022;39(2):291–301. DOI: 10.1007/s10585-021-10136-5

21. Kang D., Kim I.H. Molecular mechanisms and potential rationale of immunotherapy in peritoneal metastasis of advanced gastric cancer. Biomedicines. 2022;10(6):1376. DOI: 10.3390/biomedicines10061376

22. van Baal J.O.A.M., van Noorden C.J.F., Nieuwland R., Van de Vijver K.K., Sturk A., van Driel W.J., et al. Development of peritoneal carcinomatosis in epithelial ovarian cancer: a review. J Histochem Cytochem. 2018;66(2):67–83. DOI: 10.1369/0022155417742897

23. Cui N., Hu M., Khalil R.A. Biochemical and biological attributes of matrix metalloproteinases. Prog Mol Biol Transl Sci. 2017;147:1–73. DOI: 10.1016/bs.pmbts.2017.02.005

24. Laronha H., Caldeira J. Structure and function of human matrix metalloproteinases. Cells. 2020;9(5):1076. DOI: 10.3390/cells9051076

25. Wang X., Khalil R.A. Matrix metalloproteinases, vascular remodeling, and vascular disease. Adv Pharmacol. 2018;81:241–330. DOI: 10.1016/bs.apha.2017.08.002

26. Shahid S., Iman A., Matti U., Rachid K., Assaf A., Eveno C., et al. Fibrin deposit on the peritoneal surface serves as a niche for cancer expansion in carcinomatosis patients. Neoplasia. 2019;21(11):1091–101. DOI: 10.1016/j.neo.2019.08.006

27. Solomenny S.V., Gantsev K.Sh., Kzyrgalin Sh.R., Minigazimov R.S. Anatomical preconditions for development and clinical course for patients with peritoneal carcinomatosis. Ulyanovsk Medico-Biological Journal. 2016;3:91–9 (In Russ.).

28. Ritch S.J., Telleria C.M. The transcoelomic ecosystem and epithelial ovarian cancer dissemination. Front Endocrinol (Lausanne). 2022;13:886533. DOI: 10.3389/fendo.2022.886533

29. Dasari S., Fang Y., Mitra A.K. Cancer associated fibroblasts: naughty neighbors that drive ovarian cancer progression. Cancers (Basel). 2018;10(11):406. DOI: 10.3390/cancers10110406

30. Czekay R.P., Cheon D.J., Samarakoon R., Kutz S.M., Higgins P.J. Cancer-associated fibroblasts: mechanisms of tumor progression and novel therapeutic targets. Cancers (Basel). 2022;14(5):1231. DOI: 10.3390/cancers14051231

31. Varghese S., Burness M., Xu H., Beresnev T., Pingpank J., Alexander H.R. Site-specific gene expression profiles and novel molecular prognostic factors in patients with lower gastrointestinal adenocarcinoma diffusely metastatic to liver or peritoneum. Ann Surg Oncol. 2007;14(12):3460–71. DOI: 10.1245/s10434-007-9557-7

32. Gao Q., Yang Z., Xu S., Li X., Yang X., Jin P., et al. Heterotypic CAFtumor spheroids promote early peritoneal metastatis of ovarian cancer. J Exp Med. 2019;216(3):688–703. DOI: 10.1084/jem.20180765

33. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. DOI: 10.1016/j.cell.2011.02.013

34. Yin L., Li J., Ma D., Li D., Sun Y. Angiogenesis in primary colorectal cancer and matched metastatic tissues: Biological and clinical implications for anti-angiogenic therapies. Oncol Lett. 2020;19(5):3558–66. DOI: 10.3892/ol.2020.11450

35. Huang Z.Y., Zhang L.H., Zhao C., Liu R., Tong H., Gan C., et al. High HIF-1α expression predicts poor prognosis of patients with colon adenocarcinoma. Int J Clin Exp Pathol. 2018;11(12):5635–46. PMID: 31949650

36. Kampoli K., Foukas P.G., Ntavatzikos A., Arkadopoulos N., Koumarianou A. Interrogating the interplay of angiogenesis and immunity in metastatic colorectal cancer. World J Methodol. 2022;12(1):43–53. DOI: 10.5662/wjm.v12.i1.43

37. Dohan A., Hoeffel C., Soyer P., Jannot A.S., Valette P.J., Thivolet A., et al. Evaluation of the peritoneal carcinomatosis index with CT and MRI. Br J Surg. 2017;104(9):1244–9. DOI: 10.1002/bjs.10527

38. Chia C.S., Wong L.C.K., Hennedige T.P., Ong W.S., Zhu H.Y., Tan G.H.C., et al. Prospective comparison of the performance of MRI versus CT in the detection and evaluation of peritoneal surface malignancies. Cancers (Basel). 2022;14(13):3179. DOI: 10.3390/cancers14133179

39. Kim S.J., Lee S.W. Diagnostic accuracy of 18F-FDG PET/CT for detection of peritoneal carcinomatosis; a systematic review and meta-analysis. Br J Radiol. 2018;91(1081):20170519. DOI: 10.1259/bjr.20170519

40. Fischerova D., Zikan M., Semeradova I., Slama J., Kocian R., Dundr P., et al. Ultrasound in preoperative assessment of pelvic and abdominal spread in patients with ovarian cancer: a prospective study. Ultrasound Obstet Gynecol. 2017;49(2):263–74. DOI: 10.1002/uog.15942

41. Qi Z., Zhang Y., Dai Q., Xia Y., Jiang Y. Peritoneal carcinomatosis in primary ovarian cancer: ultrasound detection and comparison with computed tomography. Ultrasound Med Biol. 2017;43(9):1811–9. DOI: 10.1016/j.ultrasmedbio.2017.02.016

42. Laghi A., Bellini D., Rengo M., Accarpio F., Caruso D., Biacchi D., et al. Diagnostic performance of computed tomography and magnetic resonance imaging for detecting peritoneal metastases: systematic review and meta-analysis. Radiol Med. 2017;122(1):1–15. DOI: 10.1007/s11547-016-0682-x

43. Cho J.H., Kim S.S. Peritoneal carcinomatosis and its mimics: review of CT findings for differential diagnosis. J Belg Soc Radiol. 2020;104(1):8. DOI: 10.5334/jbsr.1940

44. Saiz Martínez R., Dromain C., Vietti Violi N. Imaging of gastric carcinomatosis. J Clin Med. 2021;10(22):5294. DOI: 10.3390/jcm10225294

45. van ‘t Sant I., Engbersen M.P., Bhairosing P.A., Lambregts D.M.J., Beets-Tan R.G.H., van Driel W.J., et al. Diagnostic performance of imaging for the detection of peritoneal metastases: a meta-analysis. Eur Radiol. 2020;30(6):3101–12. DOI: 10.1007/s00330-019-06524-x

46. Dohan A., Hobeika C., Najah H., Pocard M., Rousset P., Eveno C. Preoperative assessment of peritoneal carcinomatosis of colorectal origin. J Visc Surg. 2018;155(4):293–303. DOI: 10.1016/j.jviscsurg.2018.01.002

47. Leeman M.F., Patel D., Anderson J., O ̛Neill J.R., Paterson-Brown S. Multidetector computed tomography versus staging laparoscopy for the detection of peritoneal metastases in esophagogastric junctional and gastric cancer. Surg Laparosc Endosc Percutan Tech. 2017;27(5):369–74. DOI: 10.1097/SLE.0000000000000451

48. Carboni F., Federici O., Giofrè M., Valle M. An 18-year experience in diagnostic laparoscopy of peritoneal carcinomatosis: results from 744 patients. J Gastrointest Surg. 2020;24(9):2096–103. DOI: 10.1007/s11605-019-04368-w

49. Najah H., Malgras B., Dohan A., Gronnier C., Eveno C., Pocard M. The role of single-incision laparoscopic peritoneal exploration in the management of patients with peritoneal metastases. Surg Endosc. 2020;34(5):2040–9. DOI: 10.1007/s00464-019-06984-8

50. Wang P.H. The role of laparoscopy and the value of peritoneal carcinomatosis index in patients with intra-abdominal malignancies who are scheduled to laparotomy. Gynecol Minim Invasive Ther. 2019;8(2):51–2. DOI: 10.4103/GMIT.GMIT_93_18

51. Jacquet P., Sugarbaker P.H. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74. DOI: 10.1007/978-1-4613-1247-5_23

52. de Boer N.L., Brandt-Kerkhof A.R.M., Madsen E.V.E., Doukas M., Verhoef C., Burger J.W.A. The accuracy of the surgical peritoneal cancer index in patients with peritoneal metastases of colorectal cancer. Dig Surg. 2021;38(3):205–11. DOI: 10.1159/000513353

53. Bhatt A., Yonemura Y., Mehta S., Benzerdjeb N., Kammar P., Parikh L., et al. The pathologic peritoneal cancer index (PCI) strongly differs from the surgical PCI in peritoneal metastases arising from various primary tumors. Ann Surg Oncol. 2020;27(8):2985–96. DOI: 10.1245/s10434-020-08234-x